Communiqués Femasys Inc.

Actions

FEMY

US31447E2046

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 10/09/2026			Varia. 5j.	Varia. 1 janv.
2,740 ^USD	-3,18%		-10,46%	-76,22%

09/09	Femasys Inc. s'associe à CapexMD pour élargir l'accès des patients à son portefeuille de fertilité FemaSeed	CI
26/08	Femasys s'associe à UNC Health pour déployer son portefeuille de fertilité FemaSeed dans les centres de gynécologie-obstétrique de Caroline du Nord	CI

Communiqués

09/09	Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio	AQ
27/08	Femasys Partners with UNC Health to Introduce Its FemaSeed(R) Fertility Portfolio Across Statewide OB/GYN Care Locations	AQ
26/08	Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations	AQ
20/08	Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc(R)	AQ
19/08	Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®	AQ
14/08	Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update	AQ
13/08	Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents	AQ
12/08	Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents	AQ
07/08	Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million	AQ
24/06	Femasys Regains Compliance with Nasdaq Listing Requirements	AQ
13/05	Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter	GL
13/05	Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter	AQ
08/05	Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update	GL
05/05	Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete	GL
05/05	Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete	AQ
22/04	Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026	GL
16/04	Femasys : Shareholder Update – Q1 2026	PU
16/04	Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio	GL
01/04	Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth	GL
31/03	Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update	GL
18/03	Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors	GL
18/03	Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors	AQ
10/03	Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment	GL
27/02	Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
26/02	Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access	GL